One of the most significant drawbacks for a brand when partnering with individual medical journal platforms is the limitation ...

Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase ...

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Medipost transitioned from cord blood banking to developing stem cell therapies, focusing on knee osteoarthritis and other ...

Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, ...

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...